Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in obstetric general anesthesia
ChiCTR2300070965Phase 4Not yet recruiting
- Sponsor
- Tianjin Central Hospital of Obstetrics and Gynecology
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine in None (3 arms), sponsored by Tianjin Central Hospital of Obstetrics and Gynecology. Primary endpoints: Maternal plasma adrenocorticotropic hormone, Maternal plasma epinephrine and 4 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on ChiCTR2300070965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070965.